DEFA14A filed Aug 3, 2026 at 17:10 ET
Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026, updating stockholders ahead of the August 11 special meeting to vote on the $135.11/share all-cash acquisition by AbbVie. The supplement addresses a pending stockholder lawsuit (Smith Complaint) alleging inadequate disclosures, adds voluntary disclosures on financial projections and fairness opinions, and confirms German antitrust clearance (FCO) was obtained on July 27, 2026, with an Australian ACCC filing underway. The board reiterates its unanimous recommendation for approval, and non-voting stock holders have already consented. The deal remains on track with the record-date share count updated to 62,140,183 voting shares outstanding; a majority of 31,070,092 votes is needed for approval.